Quick Answer
BIOGEN INC. reported Cash and Equivalents of $2.91 billion for fiscal year 2019.
BIOGEN INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2019 | $2.91B | +137.9% |
| 2018 | $1.22B | -22.2% |
| 2017 | $1.57B | -32.4% |
| 2016 | $2.33B | +77.9% |
| 2015 | $1.31B | +8.6% |
| 2014 | $1.20B | +100.0% |
| 2013 | $602.60M | +5.6% |
| 2012 | $570.70M | +10.9% |
| 2011 | $514.54M | -32.3% |
| 2010 | $759.60M | +30.5% |
| 2009 | $581.89M | -6.5% |
| 2008 | $622.38M | -5.7% |
| 2007 | $659.66M | -0.3% |
| 2006 | $661.38M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2019 | $2.34B | -1.8% | +36.0% |
| June 30, 2019 | $1.72B | +37.8% | -23.2% |
| March 31, 2019 | $2.24B | -45.4% | +83.2% |
| December 31, 2018 | $1.22B | -22.2% | -48.7% |
| September 30, 2018 | $2.39B | +54.2% | +90.9% |
| June 30, 2018 | $1.25B | +6.9% | -69.6% |
| March 31, 2018 | $4.11B | +344.6% | +161.0% |
| December 31, 2017 | $1.57B | -32.4% | +1.7% |
- BIOGEN INC. showed an increase of +137.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2006–2019 period, BIOGEN INC.’s cash and equivalents has grown by 340.6% (from $661.38 million to $2.91 billion).
- The most recent figure is from BIOGEN INC.’s fiscal year 2019 report (Form 10-K), filed with the SEC on February 6, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: